Rosiglitazone recommended for European approval

    SmithKline Beecham announced on Thursday that the scientific committee of the European Agency for the Evaluation of Medicinal Products will recommend that rosiglitazone maleate (Avandia), the company's type 2 diabetes treatment, be approved for use in Europe in certain circumstances.

Källa: Online http://diabetes.medscape.com/19083.rhtml via Medical Reuter 17/3 2000.


Red